Services do NOT include

Extended immunology or molecular assays or bioinformatic analyses are not included, but can be offered.

Possible Output

Study plan, animal experiment approval by the institutional AWB and the Dutch Central Authority for Scientific Procedures on Animals (CCD), raw data as excel file and a summarizing report on the study, biological samples.

Sample Requirements - input of users

Well described vaccine formulations and/or SOP for vaccine formulation; user is responsible for transport of vaccines.

Lead Scientist

Dr. Norbert Stockhofe-Zurwieden, DVM, Spec. Vet. Pathol.

Immunogenicity, challenge and efficacy studies in pigs, ruminants and other farm animals - SWR

Description of service

As partner of TRANSVAC2, WBVR will provide access to their animal facilities (Lelystad) to carry out immunogenicity and efficacy studies of new candidate vaccines and/or of novel vaccination (administration) strategies in pigs, cattle, ferrets or other animal species. Efficacy studies depend on the availability of the challenge model and can be performed in biosafety containment up to BSL3. The access will comprise purchase of animals, the housing and animal care and biotechnical expertise for administration and sampling. Scientific support will include advice on experimental design and methodology, documentation of results for all experiments conducted during the project, and appropriate sampling and conservation of samples. Laboratory analyses are included to primary read-outs like haematology, immunology, pathology, but need to be defined on a case by case evaluation. WBVR will also provide the required legal approvals and ethical approval.

Timeline 

Depending on the type of animal study*

Contact 

Dr. Norbert Stockhofe-Zurwieden

Norbert.Stockhofe@wur.nl

0031 (0)320238238.

*4 months (min) , if approval by the Dutch Central Authority for Scientific Procedures on Animals (CCD); 2 months, after end of the in-life phase for analysis and reporting.

Cost coverage opportunities

 If you are interested in this service please contact the service provider directly

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative